Lineage Cell Therapeutics, Inc. Quarterly Revenues in USD from Q2 2011 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
Summary
Lineage Cell Therapeutics, Inc. quarterly/annual Revenues history and growth rate from Q2 2011 to Q4 2024.
  • Lineage Cell Therapeutics, Inc. Revenues for the quarter ending December 31, 2024 was $2.87M, a 37.4% increase year-over-year.
  • Lineage Cell Therapeutics, Inc. Revenues for the twelve months ending December 31, 2024 was $9.5M, a 6.19% increase year-over-year.
  • Lineage Cell Therapeutics, Inc. annual Revenues for 2024 was $9.5M, a 6.19% increase from 2023.
  • Lineage Cell Therapeutics, Inc. annual Revenues for 2023 was $8.95M, a 39.2% decline from 2022.
  • Lineage Cell Therapeutics, Inc. annual Revenues for 2022 was $14.7M, a 239% increase from 2021.
Revenues, Trailing 12 Months (USD)
Revenues, Quarterly (USD)
Revenues, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $9.5M $2.87M +$780K +37.4% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-10
Q3 2024 $8.72M $3.78M +$2.53M +203% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $6.19M $1.41M -$1.82M -56.3% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 $8M $1.44M -$942K -39.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $8.95M $2.09M +$173K +9.03% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 $8.77M $1.25M -$1.75M -58.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $10.5M $3.23M -$1.33M -29.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $11.9M $2.39M -$2.85M -54.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $14.7M $1.92M +$747K +64% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 $14M $3M +$728K +32.1% Jul 1, 2022 Sep 30, 2022 10-K 2024-03-07
Q2 2022 $13.2M $4.55M +$4.04M +789% Apr 1, 2022 Jun 30, 2022 10-K 2024-03-07
Q1 2022 $9.19M $5.24M +$4.85M +1239% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-07
Q4 2021 $4.34M $1.17M +$813K +229% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-09
Q3 2021 $3.53M $2.27M +$1.7M +298% Jul 1, 2021 Sep 30, 2021 10-K 2023-03-09
Q2 2021 $1.83M $512K +$126K +32.6% Apr 1, 2021 Jun 30, 2021 10-K 2023-03-09
Q1 2021 $1.7M $391K -$123K -23.9% Jan 1, 2021 Mar 31, 2021 10-K 2023-03-09
Q4 2020 $1.83M $355K Oct 1, 2020 Dec 31, 2020 10-K 2022-03-10
Q3 2020 $571K Jul 1, 2020 Sep 30, 2020 10-K 2022-03-10
Q2 2020 $386K Apr 1, 2020 Jun 30, 2020 10-K 2022-03-10
Q1 2020 $514K Jan 1, 2020 Mar 31, 2020 10-K 2022-03-10
Q3 2018 $982K -$706K -41.8% Jul 1, 2018 Sep 30, 2018 10-Q 2018-11-08
Q2 2018 $2.55M +$2.17M +569% Apr 1, 2018 Jun 30, 2018 10-Q 2018-08-02
Q3 2017 $1.69M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-08
Q2 2017 $381K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q3 2012 $1M -$158K -13.6% Jul 1, 2012 Sep 30, 2012 10-Q 2012-11-09
Q2 2012 $1.03M +$253K +32.5% Apr 1, 2012 Jun 30, 2012 10-Q 2012-08-09
Q3 2011 $1.16M Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-09
Q2 2011 $780K Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.